Dental PlaqueNCT06933368
A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
A study testing Crest Cavity Protection Toothpaste and Experimental Mouthwash in people with Dental Plaque and Gingivitis, run by HALEON at 1 site in United States.
Trial summary
The aim of this 12-week clinical study is to evaluate the ability of an experimental mouthwash, containing 0.085 percent (%) Cetylpyridinium chloride (CPC) as an adjunct to toothbrushing with a regular fluoride toothpaste, to improve gingival health and plaque accumulation compared to a regular fluoride toothpaste… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dental Plaque, Gingivitis
- What is being tested?
- Crest Cavity Protection Toothpaste and Experimental Mouthwash
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 138 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Apr 2025to 14 Aug 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
- Participant is of either sex and any gender who, at the time of screening, is at least 18 years old, inclusive.
- A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.
- A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
- Participant oral health that meets all the following:
- At screening (visit 1):
Show all 12Show fewer
- Participant with at least 20 natural, permanent teeth.
- Participant with at least 40 evaluable surfaces for MGI, bleeding index (BI), and TPI.
- A participant with plaque-induced gingivitis, in the opinion of the clinical examiner, as confirmed by a gross visual examination at the screening visit.
- At baseline (visit 2; prior to dental prophylaxis)
- A participant with 10% to 30% bleeding sites.
- A participant with overall TPI score >=1.5.
Who cannot join
- A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
- A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
- A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (for example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
- A participant who is a pregnant female (self-reported) or intending to become pregnant over the duration of the study.
- A female participant who is breastfeeding.
- A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
Show all 41Show fewer
- A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.
- A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening.
- A participant who is using smokeless forms of tobacco (for example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
- A participant who is diagnosed with xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.
- A participant who has a medical condition which could have directly influenced gingival bleeding (for example, type 2 diabetes).
- A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.
- A participant who has a recent history (within the last year) of alcohol or other substance abuse.
- A participant who has a severe oral condition (for example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
- Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
- Medication exclusions: At screening (Visit 1):
- A participant using any antibiotic medication within 4 weeks prior to screening or at any time during the study.
- A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
- A participant currently taking a systemic medication (for example, anti-inflammatory, anticoagulant, immunosuppressants) or traditional/ herbal remedy or as a premedication requirement before an invasive examinations and prophylaxis (for example, knee replacement, Mitral valve prolapse etc.), which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
- A participant who has used an antibacterial dentifrice or mouthwash (for example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, within 4 weeks prior to screening.
- Medication exclusions: At baseline (Visit 2):
- A participant who has taken (in the previous 4 weeks), any antibiotics.
- A participant who requires the need for antibiotic premedication prior to a dental prophylaxis or taking some blood thinning medication that prohibit the safe conduct of a dental cleaning. Note: Medical consultation may need to be obtained from participant's physician at the examiner's discretion.
- A participant who has taken (in the previous 4 weeks) a systemic medication (for example, anti-inflammatory, anti-coagulant, immunosuppressants) or traditional/ herbal remedy as a premedication requirement before an invasive examinations and prophylaxis (for example, knee replacement, Mitral valve prolapse etc.), which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
- A participant who has used an antibacterial dentifrice or mouthwash (for example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, in the period between Screening and the Baseline visit.
- Periodontal exclusions:
- A participant who has more than three tooth sites with probing pocket depth >=4 mm.
- A participant who is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
- A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
- Dental exclusions:
- A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
- A participant who has dentures (partial or full).
- A participant who has an orthodontic appliance (bands, appliances, or fixed/ removable retainers).
- A participant who received orthodontic therapy within 3 months of Screening.
- A participant who has numerous restorations in a poor state of repair.
- A participant who has any dental condition (for example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
- A participant who has had dental prophylaxis within 12 weeks of Screening.
- A participant who has had teeth bleaching within 12 weeks of Screening.
- A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.
- A participant who has previously been enrolled in this study.
- A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A 12-Week, Randomized, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
The aim of this 12-week clinical study is to evaluate the ability of an experimental mouthwash, containing 0.085 percent (%) Cetylpyridinium chloride (CPC) as an adjunct to toothbrushing with a regular fluoride toothpaste, to improve gingival health and plaque accumulation compared to a regular fluoride toothpaste alone in participants with plaque-induced mild to moderate gingivitis.
Read the detailed description
This will be a single-center, 12-week, randomized, controlled, single blind (examiner only), 2-treatment arms, parallel group, stratified (by sex [male/female]) study, investigating gingival health and subgingival plaque reduction on healthy participants after twice daily using of an experimental mouthwash containing 0.085% weight/weight (w/w) CPC in combination with a commercially available regular toothpaste containing 0.243% w/w Sodium Fluoride (NaF) compared to a commercially available regular toothpaste containing 0.243% w/w NaF with no known anti-gingivitis nor anti plaque efficacy properties as control group. Approximately 132 participants (approximately 66 per group) will be randomized to ensure approximately 120 evaluable participants (approximately 60 per group) complete the study.
- Conditions
- Dental Plaque, Gingivitis
- Being tested
- Crest Cavity Protection Toothpaste, Experimental Mouthwash
- Medical subject headings
- Dental Plaque, Gingivitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Crest Cavity Protection ToothpasteDrug
Toothpaste containing 0.243% w/w NaF.
Experimental MouthwashDrug
Mouthwash containing 0.085% w/w CPC.
| Study group | Role | What they receive |
|---|---|---|
| Test Products (Toothpaste + Mouthwash) | Experimental | Participants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks. After each brushing, participants will swish 20 milliliter (ml) of experimental mouthwash for 30 seconds without rinsing with water after use of mouthwash. Receives: Drug: Crest Cavity Protection Toothpaste; Drug: Experimental Mouthwash |
| Reference Product (Toothpaste) | Active comparator | Participants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks. Receives: Drug: Crest Cavity Protection Toothpaste |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product)
Gingival bleeding was assessed according to the Expanded Bleeding Index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Measured: Week 12
Secondary outcomes (9)
Interproximal NBS at Week 12 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Measured: Week 12
Overall NBS at Week 6 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Measured: Week 6
Interproximal NBS at Week 6 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Measured: Week 6
Mean Overall EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.
Measured: Week 6 and Week 12
Mean Interproximal EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0= no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.
Measured: Week 6 and Week 12
Mean Overall Modified Gingival Index (MGI) at Week 6 and Week 12 (Test Products vs. Reference Product)
The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.
Measured: Week 6 and Week 12
Mean Interproximal MGI at Week 6 and Week 12 (Test Products vs. Reference Product)
The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.
Measured: Week 6 and Week 12
Mean Overall Turesky Plaque Index (TPI) at Week 6 and Week 12 (Test Products vs. Reference Product)
The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter [mm]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (<) 1/3 of the tooth surface, 4= Plaque covering more than or equal to (>=) 1/3 but < 2/3 of the tooth surface, 5= Plaque covering >= 2/3 of the tooth surface. Lower score indicated improvement.
Measured: Week 6 and Week 12
Mean Interproximal TPI at Week 6 and Week 12 (Test Products vs. Reference Product)
The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering < 1/3 of the tooth surface, 4= Plaque covering >= 1/3 but < 2/3 of the tooth surface, 5= Plaque covering >= 2/3 of the tooth surface. Lower score indicated improvement.
Measured: Week 6 and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2025
- Study start21 Apr 2025
- Primary completion14 Aug 2025
- Study completion14 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Dental PlaqueStudies of the same condition, open and under way.
- More trials run by HALEONThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 138 participants (actual)
Sponsor and investigators
- Lead sponsor
- HALEON
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06933368
- Sponsor's protocol ID
- 300268
- Status last verified
- Jul 2026
- First submitted
- 16 Apr 2025
- Last updated
- 26 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trialregister@haleon.com.
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 12-Week, Randomized, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
- ClinicalTrials.gov ID
- NCT06933368
- Acronym / sponsor ID
- 300268
- Conditions
- Dental Plaque, Gingivitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 138 participants (actual)
- Lead sponsor
- HALEONIndustry (pharma, biotech, devices)
- Study start
- 21 Apr 2025 (actual)
- Primary completion
- 14 Aug 2025 (actual)
- Study completion
- 14 Aug 2025 (actual)
- First posted
- 18 Apr 2025 (actual)
- Results
- Posted 26 Oct 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this 12-week clinical study is to evaluate the ability of an experimental mouthwash, containing 0.085 percent (%) Cetylpyridinium chloride (CPC) as an adjunct to toothbrushing with a regular fluoride toothpaste, to improve gingival health and plaque accumulation compared to a regular fluoride toothpaste alone in participants with plaque-induced mild to moderate gingivitis.
Detailed description
This will be a single-center, 12-week, randomized, controlled, single blind (examiner only), 2-treatment arms, parallel group, stratified (by sex [male/female]) study, investigating gingival health and subgingival plaque reduction on healthy participants after twice daily using of an experimental mouthwash containing 0.085% weight/weight (w/w) CPC in combination with a commercially available regular toothpaste containing 0.243% w/w Sodium Fluoride (NaF) compared to a commercially available regular toothpaste containing 0.243% w/w NaF with no known anti-gingivitis nor anti plaque efficacy properties as control group. Approximately 132 participants (approximately 66 per group) will be randomized to ensure approximately 120 evaluable participants (approximately 60 per group) complete the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test Products (Toothpaste + Mouthwash) | Experimental | Drug: Crest Cavity Protection Toothpaste, Drug: Experimental MouthwashParticipants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks. After each brushing, participants will swish 20 milliliter (ml) of experimental mouthwash for 30 seconds without rinsing with water after use of mouthwash. |
| Reference Product (Toothpaste) | Active comparator | Drug: Crest Cavity Protection ToothpasteParticipants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
- Participant is of either sex and any gender who, at the time of screening, is at least 18 years old, inclusive.
- A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.
- A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
- Participant oral health that meets all the following:
Key exclusion criteria (41 listed)
- A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
- A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
- A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (for example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
- A participant who is a pregnant female (self-reported) or intending to become pregnant over the duration of the study.
- A female participant who is breastfeeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Crest Cavity Protection ToothpasteToothpaste containing 0.243% w/w NaF. | Drug | Reference Product (Toothpaste), Test Products (Toothpaste + Mouthwash) |
| Experimental MouthwashMouthwash containing 0.085% w/w CPC. | Drug | Test Products (Toothpaste + Mouthwash) |
Primary outcome
Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product)
Time frame: Week 12
Gingival bleeding was assessed according to the Expanded Bleeding Index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
9 secondary outcomes
Interproximal NBS at Week 12 (Test Products vs. Reference Product)
Time frame: Week 12
Overall NBS at Week 6 (Test Products vs. Reference Product)
Time frame: Week 6
Interproximal NBS at Week 6 (Test Products vs. Reference Product)
Time frame: Week 6
Mean Overall EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
Time frame: Week 6 and Week 12
Mean Interproximal EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
Time frame: Week 6 and Week 12
Mean Overall Modified Gingival Index (MGI) at Week 6 and Week 12 (Test Products vs. Reference Product)
Time frame: Week 6 and Week 12
Mean Interproximal MGI at Week 6 and Week 12 (Test Products vs. Reference Product)
Time frame: Week 6 and Week 12
Mean Overall Turesky Plaque Index (TPI) at Week 6 and Week 12 (Test Products vs. Reference Product)
Time frame: Week 6 and Week 12
Mean Interproximal TPI at Week 6 and Week 12 (Test Products vs. Reference Product)
Time frame: Week 6 and Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trialregister@haleon.com.
Related trials for Dental Plaque
Active, not recruitingPhase 3
A Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis
Plaque, Gingivitis
Not yet recruiting
Effectiveness of Personalized Digital Oral Health Intervention in Patients With Fixed Orthodontic Appliances.
Oral Hygiene in Patients With Fixed Orthodontic Appliances, Dental Plaque
Not yet recruiting
Effect of Xylitol- Versus Erythritol-Sweetened Mints on Plaque ATP-Bioluminescence Readings
Dental Caries, Dental Plaque
Not yet recruitingObservational study
Plaque and Bleeding on Probing Around Implants Supporting Fixed Full-Arch Dental Prostheses
Peri-Implant Health
Not yet recruiting
Effectiveness of Oil Pulling Using Oils in Comparison With Mouthwash for Gingivitis
Gingivitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Crest Cavity Protection Toothpaste and Experimental Mouthwash in people with Dental Plaque and Gingivitis, run by HALEON at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 41 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product) (time frame: Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.